This Plain Language Summary from Future Oncology provides an overview of two of the main clinical studies that led to the approval of a medication called tepotinib. The article summarises how the participants with MET exon 14 skipping NSCLC who took tepotinib had their tumour growth stopped or shrunk and what side effects they experienced.

Read the full article here.

This plain language summary provides an overview of two of the main clinical studies that led to tepotinib’s approval, the phase I first-in-human study and the phase II VISION study

The original article discussed in this summary are:

  • ‘First-in-man Phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors’ (Study 1), published in Clinical Cancer Research. Read the article here.
  • ‘Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations’ (Study 2), published in New England Journal of Medicine. Read the article here.
  • ‘Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice’ (Study 2), published in Clinical Cancer Research. Read the article here.
  • ‘Safety of tepotinib in patients with MET exon 14 skipping NSCLC and recommendations for management’ (Study 2), published in Clinical Lung Cancer. Read the article here.